Johns Hopkins, the Maryland Stem Cell Research Fund and BioCardia (NSDQ:BCDA) said today that the 1st patient has been treated in a pivotal Phase III trial of the CardiAmp cell-based therapy for the treatment of ischemic heart failure.
The investigational therapy was designed to deliver a dose of a patient’s own bone marrow cells directly to the area of cardiac dysfunction after a heart attack, according to BioCardia.
Get the full story at our sister site, Drug Delivery Business News.